Navigation Links
Personalized treatment for early lung cancer
Date:5/3/2009

Cancer vaccines and targeted therapies are beginning to offer new treatment options following surgery for patients with early stages of lung cancer, experts said at the first European Multidisciplinary Conference in Thoracic Oncology (EMCTO) in Lugano, Switzerland (1-3 May 2009).

"Personalizing therapy is the key strategy for longer and better survival in lung cancer," said Prof Paris Kosmidis, head of the second Medical Oncology Department at Hygeia Hospital in Athens, Greece. "This is particularly important for early stage disease when following surgery, decisions about preventive therapy are based on specific prognostic and predictive factors."

Prof Walter Weder, head of thoracic surgery at the University of Zurich in Switzerland, adds: "At the meeting, several research groups will present data from new and ongoing studies that show how existing treatments might be combined with targeted therapies and new cancer vaccines. We hope that these new treatments will provide further progress."

In one poster presentation at the meeting, researchers describe the results of a study that sought to identify which patients are likely to benefit from an immune-boosting vaccine designed to help the immune system recognize MAGE-A3, a protein that is expressed on about 30% of lung cancers.

Studies have shown that the treatment can help patients avoid or delay cancer recurrence after surgery. At the conference, researchers will describe a gene signature that might predict which patients will benefit from the treatment.

"Because the benefits of vaccination will be limited to a subgroup of patients, strategies to define these patients by means of biomarkers such as a genetic signature are of major clinical relevance, as only these patients might be candidates for vaccination in the future." A larger, phase III, trial of the vaccine is now underway.

The European Multidisciplinary Conference on Thoracic Oncology is organize
'/>"/>

Contact: ESMO Press Office
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Nutrigenomics -- developing personalized diets for disease prevention -- part 2 just published in OMICS
2. Digital communication technology helps clear path to personalized therapies
3. Nutrigenomics -- developing personalized diets for disease prevention
4. Personalized medicine: Innovative online journal leads the way
5. Researchers at UH explore patient preferences for personalized medicine
6. New clinical trial results show how personalized medicine will alter treatment of genetic disorders
7. Emory, Ohio State launch partnership in predictive and personalized health care
8. New genetic research into nicotine addiction shows promise for personalized treatment
9. Joining forces to improve lung cancer treatment
10. Poor treatment for common vertebral compression fractures
11. New light on bipolar treatment drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2